Key Stats for Eli Lilly Stock
- Price change for Eli Lilly stock: -4%
- $LLY Share Price as of Apr. 24: $884
- 52-Week High: $1,134
- $LLY Stock Price Target: $1,211
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Eli Lilly (LLY) stock dropped nearly 4% on Friday after early prescription data for its new oral weight loss pill, Foundayo, came in well below expectations.
- Foundayo is Lilly’s once-daily oral GLP-1 drug — the same category as Novo Nordisk’s Wegovy pill.
- In its first full week on the market, Foundayo recorded just 3,707 total prescriptions.
- That’s only about 20% of what Novo’s oral Wegovy achieved during its own first week in January.
That gap rattled investors.
- Truist analyst Srikripa Devarakonda acknowledged it’s early, but noted that “investors will be scrutinizing the numbers” and that the soft start “could cause the stock to be weak today.” It did.
- At the same time, injectable Zepbound prescriptions fell about 2% week-over-week for the week ending April 17.
- Meanwhile, Novo’s injectable Wegovy grew 7% over that same period.
- Neither trend helped the sentiment around Eli Lilly stock.
The most likely explanation for Foundayo’s slow start is brand recognition. Wegovy has been marketed heavily to consumers for years. Foundayo is new.
Analysts are hesitant to draw firm conclusions from a single week of data, but the comparison to oral Wegovy’s launch is hard to ignore.
It’s worth stepping back. Lilly’s underlying business remains strong.
- Full-year 2025 revenue grew 45% to $65.2 billion.
- Zepbound holds nearly 70% of new prescriptions in the branded obesity market.
- Lilly expects 2026 revenue between $80 billion and $83 billion, driven by continued incretin growth and the Foundayo launch.
Management has said publicly that oral GLP-1s expand the market rather than cannibalize existing injectable demand.
Early data from Novo’s oral Wegovy launch supported that view. Whether Foundayo follows the same path is the question the market is now asking.
See analysts’ growth forecasts and price targets for Eli Lilly stock (It’s free) >>>
What the Market Is Telling Us About Eli Lilly Stock
Eli Lilly stock is already down about 18% this year, well off its 52-week high.
Today’s move reflects real concern about whether Foundayo can compete with Novo’s oral Wegovy, which had a significant head start and stronger brand awareness in the oral segment.
One week of prescription data is not a verdict.
But for Eli Lilly stock to recover from its recent slide, investors need to see Foundayo gain traction quickly. The next several weeks of IQVIA data will matter a lot.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Eli Lilly Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
